|
|
Volumn 63 Suppl 1, Issue , 2002, Pages 17-24
|
|
Perspectives on anti-HER monoclonal antibodies.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
LIGAND;
MAYTANSINE;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
BIOLOGICAL MODEL;
CHEMICAL MODEL;
CHEMISTRY;
CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
GENETICS;
HUMAN;
METABOLISM;
REVIEW;
TIME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS;
DISEASE-FREE SURVIVAL;
HUMANS;
LIGANDS;
MAYTANSINE;
MODELS, BIOLOGICAL;
MODELS, CHEMICAL;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
RECEPTOR, ERBB-2;
TIME FACTORS;
|
|
EID: 2442659899
PISSN: 00302414
EISSN: None
Source Type: Journal
DOI: 10.1159/000066203 Document Type: Review |
|
Times cited : (61)
|
|
References (49)
|
